Dianthus Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Dianthus Therapeutics
DNTH Stock   41.21  0.25  0.61%   
Dianthus Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Dianthus Therapeutics' valuation are provided below:
Gross Profit
3.1 M
Market Capitalization
1.8 B
Enterprise Value Revenue
449.3735
Revenue
3.1 M
Earnings Share
(3.50)
We have found one hundred twenty available fundamental signals for Dianthus Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Dianthus Therapeutics prevailing fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 58.6 M. The Dianthus Therapeutics' current Enterprise Value is estimated to increase to about (85.4 M)

Dianthus Therapeutics Total Revenue

4.66 Million

Check Dianthus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dianthus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 391.4 K, Interest Expense of 2.7 M or Selling General Administrative of 16.3 M, as well as many indicators such as Price To Sales Ratio of 83.61, Dividend Yield of 0.0 or PTB Ratio of 1.96. Dianthus financial statements analysis is a perfect complement when working with Dianthus Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Dianthus Stock
Check out the analysis of Dianthus Therapeutics Correlation against competitors.
For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.

Dianthus Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets392.7 M374 M114.6 M
Slightly volatile
Other Current Liabilities7.9 M13.1 M4.8 M
Slightly volatile
Total Current Liabilities10.9 M18.5 M7.1 M
Slightly volatile
Total Stockholder Equity370.1 M352.5 M105.1 M
Slightly volatile
Property Plant And Equipment Net3.1 M1.7 M2.5 M
Slightly volatile
Accounts Payable2.8 M4.6 M2.3 M
Slightly volatile
Cash21.7 M22.8 M36.8 M
Slightly volatile
Non Current Assets Total97.8 M93.1 M15.2 M
Slightly volatile
Cash And Short Term Investments146 M275.2 M85.5 M
Slightly volatile
Net Receivables766.6 K807 K3.7 M
Slightly volatile
Common Stock Shares Outstanding35 M33.3 M6.6 M
Slightly volatile
Liabilities And Stockholders Equity392.7 M374 M114.6 M
Slightly volatile
Other Current Assets2.8 M4.9 M1.7 M
Slightly volatile
Other Stockholder Equity275.8 M526.7 M158.6 M
Slightly volatile
Total Liabilities14 M21.5 M8.9 M
Slightly volatile
Total Current Assets150.5 M280.9 M90.4 M
Slightly volatile
Common Stock36.2 K31 K21.9 K
Slightly volatile
Other Assets146.1 K139.2 K38.6 K
Slightly volatile
Short Term Investments265.1 M252.4 M99.6 M
Slightly volatile
Non Current Liabilities Total2.9 M3.1 M2.4 M
Slightly volatile
Inventory613.8 K979.8 K404.1 K
Slightly volatile
Property Plant And Equipment Gross1.1 M1.9 M330 K
Slightly volatile
Net Working Capital139.7 M262.5 M43.3 M
Slightly volatile
Property Plant Equipment1.2 M1.1 M285.1 K
Slightly volatile
Short and Long Term Debt Total1.1 M1.5 M835.6 K
Slightly volatile
Other Liabilities632.8 K711.9 K776.2 K
Slightly volatile
Current Deferred Revenue249 K479 K133 K
Slightly volatile
Short Term Debt289.9 K320 K348.6 K
Pretty Stable

Dianthus Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization391.4 K412 K527.5 K
Slightly volatile
Interest Expense2.7 M4.1 M2.1 M
Slightly volatile
Selling General Administrative16.3 M25 M10.7 M
Slightly volatile
Selling And Marketing Expenses443.3 K408.2 K245 K
Slightly volatile
Other Operating Expenses58.2 M108.1 M36.9 M
Slightly volatile
Research Development87.3 M83.1 M28.8 M
Slightly volatile
Cost Of Revenue391.4 K412 K527.5 K
Slightly volatile
Total Operating Expenses57.6 M108.1 M36.5 M
Slightly volatile
Net Interest Income18.2 M17.4 M2.5 M
Slightly volatile
Interest Income18.2 M17.4 M2.5 M
Slightly volatile
Total Revenue4.7 M6.2 M2.4 M
Slightly volatile

Dianthus Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation13.5 M12.9 M4.3 M
Slightly volatile
Begin Period Cash Flow139 M132.4 M33.5 M
Slightly volatile
Depreciation391.4 K412 K527.5 K
Slightly volatile
Capital Expenditures99.8 K105 K1 M
Very volatile
Total Cash From Financing Activities268.4 M255.6 M78.9 M
Slightly volatile
End Period Cash Flow21.9 M23 M36.8 M
Slightly volatile
Issuance Of Capital Stock282.7 M269.2 M56.5 M
Slightly volatile
Change To Netincome536.2 K1 M260.3 K
Slightly volatile
Change To Liabilities3.2 M2.9 M4.5 M
Slightly volatile
Change To Inventory3.3 M3.7 M4.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio83.61116138
Slightly volatile
Days Sales Outstanding44.8847.2422270
Slightly volatile
Stock Based Compensation To Revenue2.172.0680.3758
Slightly volatile
Capex To Depreciation0.240.254911.2758
Slightly volatile
Inventory Turnover0.140.160.1697
Slightly volatile
Days Of Inventory On Hand1.7 K1.9 K2.1 K
Slightly volatile
Payables Turnover0.08550.090.352
Pretty Stable
Sales General And Administrative To Revenue2.564.00871.8717
Slightly volatile
Research And Ddevelopement To Revenue7.6213.32888.7272
Pretty Stable
Capex To Revenue0.01990.01680.0229
Very volatile
Cash Per Share7.858.26219.2984
Slightly volatile
Days Payables Outstanding3.9 K4.1 K45.4 K
Slightly volatile
Income Quality0.640.92010.7489
Slightly volatile
Net Debt To EBITDA0.20.210.7104
Pretty Stable
Current Ratio8.9415.22358.6116
Slightly volatile
Receivables Turnover3.947.72612.0234
Slightly volatile
Capex Per Share0.0030.00320.4164
Very volatile
Revenue Per Share0.180.18720.4866
Pretty Stable
Interest Debt Per Share0.04250.04480.4141
Pretty Stable
Debt To Assets0.00610.0040.0085
Slightly volatile
Operating Cycle44.8847.24222 K
Slightly volatile
Days Of Payables Outstanding3.9 K4.1 K45.4 K
Slightly volatile
Ebt Per Ebit0.950.83410.9235
Slightly volatile
Quick Ratio8.9315.22358.6045
Slightly volatile
Cash Ratio1.171.23523.8134
Pretty Stable
Days Of Inventory Outstanding1.7 K1.9 K2.1 K
Slightly volatile
Days Of Sales Outstanding44.8847.2422270
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.00131.0402
Pretty Stable
Fixed Asset Turnover3.393.56934.6207
Slightly volatile
Debt Ratio0.00610.0040.0085
Slightly volatile
Price Sales Ratio83.61116138
Slightly volatile
Asset Turnover0.01580.01670.125
Slightly volatile

Dianthus Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap58.6 M61.6 M376 M
Slightly volatile

Dianthus Fundamental Market Drivers

Dianthus Upcoming Events

8th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Dianthus Therapeutics Financial Statements

Investors use fundamental indicators, such as Dianthus Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Dianthus Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue479 K249 K
Cost Of Revenue412 K391.4 K
Total Revenue6.2 M4.7 M
Stock Based Compensation To Revenue 2.07  2.17 
Sales General And Administrative To Revenue 4.01  2.56 
Research And Ddevelopement To Revenue 13.33  7.62 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.19  0.18 
Ebit Per Revenue(16.34)(17.15)

Currently Active Assets on Macroaxis

DDDupont De Nemours
CRDOCredo Technology Group
GOOGAlphabet Inc Class C
BACBank of America
CRMSalesforce
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:
How To Invest In Dianthus
Details
Is Dianthus Stock a good investment?
Details
What is Dianthus Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Dianthus Therapeutics Correlation against competitors.
For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.50)
Revenue Per Share
0.085
Quarterly Revenue Growth
(0.82)
Return On Assets
(0.19)
Return On Equity
(0.29)
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY